BioMarin, BMRN
BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.
The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...
Full Year 2024 Results Key Financial Results Revenue: US$2.85b (up 18% from ...
Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...
Shares of BioMarin Pharmaceutical climbed after better fourth-quarter earnings and revenue topped analyst views and the company provided upbeat revenue guidance. The stock was up 5% at $68.87 in ...
Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $126 from $122 and keeps an Overweight rating on the shares following a Q4 ...
3d
Zacks.com on MSNBioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 ViewBioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results